China Resources Sanjiu Medical & Pharmaceutical (000999.SZ) Earnings Analysis

China Resources Sanjiu Medical & Pharmaceutical (000999.SZ) next reports earnings on 2026-08-22, consensus EPS 0.3945 CNY. Last quarter (2026-04-24) it beat with EPS 0.65 CNY vs 0.63 CNY est (+3.2%). It has beaten estimates in 3/7 recent quarters (43%). Trailing P/E 12.76.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does 000999.SZ next report earnings?

Next earnings date2026-08-22
Consensus EPS estimate0.3945 CNY
Revenue estimate7.24B

000999.SZ earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-04-240.65 CNY0.63 CNY+3.2%Beat
2026-02-060.64 CNY0.715 CNY-10.5%Miss
2025-10-240.3249 CNY0.3962 CNY-18%Miss
2025-04-280.99 CNY0.6 CNY+65%Beat
2025-02-100.31 CNY0.32 CNY-3.1%Miss
2024-10-250.45 CNY0.6 CNY-25%Miss
2024-08-230.8 CNY0.78 CNY+2.6%Beat

Beat rate: 3/7 (43%) over reported quarters with consensus data.

000999.SZ valuation and analyst view

Trailing P/E12.76
Trailing EPS2.404 CNY
Price / book1.41
Dividend yield4.14%
Market cap41.87B

Limited or no published sell-side analyst coverage for this symbol.

Related research pages

Frequently asked questions

When is China Resources Sanjiu Medical & Pharmaceutical (000999.SZ)'s next earnings date?

China Resources Sanjiu Medical & Pharmaceutical is next scheduled to report on 2026-08-22, with a consensus EPS estimate of 0.3945 CNY and revenue estimate of 7.24B.

Did 000999.SZ beat earnings last quarter?

In its 2026-04-24 report, 000999.SZ posted EPS of 0.65 CNY versus a 0.63 CNY estimate — a beat of 3.2%.

What is 000999.SZ's earnings track record?

Over the last 7 reported quarters with consensus data, 000999.SZ beat estimates 3 times (43%).

What is 000999.SZ's current P/E ratio and EPS?

000999.SZ trades at a trailing P/E of 12.76 on trailing EPS of 2.4039212949267434 CNY.

What do analysts rate 000999.SZ?

000999.SZ has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.